National Policy Resources—Local Advocacy Results

As cancer care professionals who experience the challenges of providing quality cancer care first-hand, MSCO members are well positioned to educate decision-makers on how coverage and reimbursement issues affect community oncology. State and federal legislation can have a significant impact on the financial viability of local cancer programs, which is why it's so important that our members make their voices heard.

In an effort to provide resources needed to effectively advocate on the issues that are important to them, our redesigned advocacy webpage features activity from the Centers for Medicare & Medicaid Services (CMS), national healthcare coverage through the Association of Community Cancer Centers (ACCC), local news articles and webinars, and more.

We want to hear from you! If there is a specific piece of legislation you want to know more about, an important resource we're missing, or if you want to get more involved, please contact us!

State Advocacy

MSCO Joins in Support Letter for HF 3717 and Its Provisions to Address Out-of-Pocket Costs for Patients

The Minnesota Society of Clinical Oncology (MSCO) joined national organizations in a support letter for copy-only bill language in HF 3717 inspired by HF 633 (Bierman) and SF 365 (Nelson). This language would give consumers who purchase coverage on the individual and small-group markets the option of buying a plan that restructures the out-of-pocket costs for prescription drugs.

Read Letter

Federal Advocacy

MSCO Joins Coalition Letter Urging Addition of the Cures 2.0 Concept Paper Title IV Provisions in the Next COVID-19 Relief Package

The Minnesota Society of Clinical Oncology (MSCO) joined in a coalition letter to congressional leadership urging that Congress include the 21st Century Cures 2.0 concept paper, recently released by Representatives Diana DeGette and Fred Upton in upcoming legislation to further address the COVID-19 public health crisis. Specifically the letter urges leadership to include policy to provide Medicaid coverage of the routine care costs of clinical trials participation for patients with life-threatening conditions in every state. This critical protection is championed by Representatives Ben Ray Luján and Gus Bilirakis in the Clinical Treatment Act (H.R. 913).


Advocacy In the News

CMS Releases Final Rule to the Radiation Oncology Model

On November 2, 2021, the Centers for Medicare & Medicaid Services (CMS) released the CY 2022 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems final rule (CMS-1753-F). This announcement includes the finalized modifications to the Radiation Oncology (RO) Model.

The RO Model is set to begin January 1, 2022, and end December 31, 2026. The proposed rule includes the summarized modifications below:

  • Adjustment to the pricing methodology (updated baseline period is 2017 to 2019 and lowered discounts to 3.5 and 4.5) for the professional component and technical component, respectively
  • Removal of brachytherapy from included modalities
  • Removal of liver cancer from included cancer types
  • Finalization of cases in which a beneficiary switches from traditional fee-for-service (FFS) to Medicare Advantage during an episode and before treatment is complete. CMS will consider this an incomplete episode and radiation therapy services will be paid under FFS.
  • Modification to the current Pennsylvania Rural Health Model (PARHM) overlap policy to only exclude hospitals participating in the model, no just PARHM-eligible hospitals
  • Addition of an overlap policy for the Community Track of the CHART Model
  • Addition of an extreme and uncontrollable circumstances policy.

For additional information on the RO Model and CMS' final rules, visit the RO Model website or read more on thefinal rule. For questions on the model or for participants needing their model ID, contact

Posted 11/3/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us